FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Original Application (Par Health USA, LLC)

View source ↗

Summary

The FDA approved Par Health USA, LLC's Lamotrigine Extended Release as a new generic product under an original ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• Lamotrigine Extended-Release (Lamotrigine extended-release)

Snippet

ORIG AP for LAMOTRIGINE EXTENDED RELEASE (LAMOTRIGINE EXTENDED RELEASE)